Abstract
The use of anti-tumor necrosis factor-a (TNF-a) therapies has led to improved outcomes in the treatment of rheumatoid arthritis (RA). However, the use of these new therapeutic agents requires careful monitoring for adverse effects. We describe 3 patients who developed neurological disease closely associated with the use of infliximab, a monoclonal antibody that binds to and inactivates TNF-a. All had evidence of polyneuropathy, demyelinating in one and axonal in 2. One patient had a central nervous system syndrome. Physicians should be aware of these potential adverse effects when treating patients with infliximab.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / therapeutic use
-
Antirheumatic Agents / adverse effects*
-
Antirheumatic Agents / therapeutic use
-
Arthritis, Rheumatoid / drug therapy*
-
Demyelinating Diseases / chemically induced
-
Demyelinating Diseases / pathology
-
Demyelinating Diseases / physiopathology
-
Female
-
Humans
-
Infliximab
-
Middle Aged
-
Nervous System / drug effects
-
Nervous System / pathology
-
Nervous System / physiopathology
-
Polyneuropathies / chemically induced*
-
Polyneuropathies / pathology
-
Polyneuropathies / physiopathology
Substances
-
Antibodies, Monoclonal
-
Antirheumatic Agents
-
Infliximab